No­vo Nordisk sees more to GLP-1's fu­ture in $600M pact with Flag­ship's Metaphore

No­vo Nordisk is pair­ing up with an­oth­er Flag­ship-found­ed biotech to cre­ate new obe­si­ty med­ica­tions, and GLP-1 re­mains in the frame.

The Dan­ish phar­ma gi­ant, which leads the GLP-1 field along­side Eli Lil­ly, will tap in­to the “mol­e­c­u­lar mim­ic­ry” work at Metaphore Biotech­nolo­gies to make one or two obe­si­ty man­age­ment ther­a­peu­tics, the com­pa­nies said Thurs­day morn­ing.

No­vo will de­liv­er up to $600 mil­lion in up­front pay­ments and biobucks to Metaphore and Flag­ship’s Pi­o­neer­ing Med­i­cines. No­vo and Pi­o­neer­ing Med­i­cines have a broad re­la­tion­ship that al­so in­cludes an obe­si­ty pact with Omega Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER